Class Actions · Mass Torts · Securities FraudCall (918) 238-6445

Attorney advertisingBriefConsumer & Data Privacy

Taro renews bid to block state AGs' price-fixing claims via $200M MDL deal

Responsible attorney: Lou Schwartz, Schwartz & Associates, PC, Atlanta, Georgia. intake@snalawyers.com

Taro Pharmaceuticals told a Connecticut federal judge on November 18, 2026 that its $200 million settlement with end-payer plaintiffs in the generic-drug price-fixing MDL should bar a separate set of consumer price-fixing claims brought by dozens of state attorneys general. The dispute arises in the long-running In re Generic Pharmaceuticals Pricing Antitrust Litigation, where state enforcers have argued their claims and plaintiffs are too distinct from the MDL class to be bound by Taro's settlement.

Why it matters. The outcome will determine whether consumers harmed by alleged generic-drug price-fixing can pursue recovery through state AG enforcement actions even after a drugmaker has settled parallel private claims, a question relevant to other multi-track price-fixing recoveries the firm tracks.

Ask the intake assistant about this

Sources

  1. Law360 secondary

Briefs summarize public developments. Unless stated otherwise, the firm is not counsel in the matters described, and allegations are not findings.

General information, not legal advice. Reading this article or using the intake assistant does not create an attorney-client relationship.

If something happened to more people than you, tell us.

Many class actions begin with one person who noticed a pattern. Reviewing your information costs nothing and creates no obligation.